MedTrace Logo

Evaluation of the Use of Cefoxitin in Combination in Continuous Parenteral Administration in the Treatment of Bone and Joint Infections

NCT03848104 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2019-02-22

No results posted yet for this study

Summary

Cephamycin related to 2nd generation cephalosporins, the use of cefoxitin has long been limited to antibiotic prophylaxis. Because of its spectrum (sensitive staphylococci, enterobacteria including ESBL, streptococci, anaerobes), its stability and its low cost, it could be useful in curative bone and joint infections, especially in case of infection polymicrobial disease in patients for whom antibiotic alternative per os is limited.

Conditions

  • Antibiotic Reaction
  • Bone and Joint Infection

Interventions

OTHER

bone and joint infection treated with cefoxitin

the patients had cefoxitin in combination in continuous parenteral administration to treat their bone / joint infection

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Tristan Ferry, Md,PhD · Hospices Civils de Lyon

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2018-03-01
Completion
2018-04-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03848104 on ClinicalTrials.gov